These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24616262)

  • 1. Characterization, biomarkers, and reversibility of a monoclonal antibody-induced immune complex disease in cynomolgus monkeys (Macaca fascicularis).
    Heyen JR; Rojko J; Evans M; Brown TP; Bobrowski WF; Vitsky A; Dalton S; Tripathi N; Bollini SS; Johnson T; Lin JC; Khan N; Han B
    Toxicol Pathol; 2014 Jun; 42(4):765-73. PubMed ID: 24616262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formation, clearance, deposition, pathogenicity, and identification of biopharmaceutical-related immune complexes: review and case studies.
    Rojko JL; Evans MG; Price SA; Han B; Waine G; DeWitte M; Haynes J; Freimark B; Martin P; Raymond JT; Evering W; Rebelatto MC; Schenck E; Horvath C
    Toxicol Pathol; 2014 Jun; 42(4):725-64. PubMed ID: 24705884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies.
    Stubenrauch K; Wessels U; Essig U; Vogel R; Schleypen J
    J Pharm Biomed Anal; 2010 Jun; 52(2):249-54. PubMed ID: 20083366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypersensitivity Reactions to Obinutuzumab in Cynomolgus Monkeys and Relevance to Humans.
    Husar E; Solonets M; Kuhlmann O; Schick E; Piper-Lepoutre H; Singer T; Tyagi G
    Toxicol Pathol; 2017 Jul; 45(5):676-686. PubMed ID: 28830332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular composition of drusen and possible involvement of anti-retinal autoimmunity in two different forms of macular degeneration in cynomolgus monkey (Macaca fascicularis).
    Umeda S; Suzuki MT; Okamoto H; Ono F; Mizota A; Terao K; Yoshikawa Y; Tanaka Y; Iwata T
    FASEB J; 2005 Oct; 19(12):1683-5. PubMed ID: 16099945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Male and female fertility assessment in the cynomolgus monkey following administration of ABT-874, a human Anti-IL-12/23p40 monoclonal antibody.
    Enright BP; Tornesi B; Weinbauer GF; Blaich G
    Birth Defects Res B Dev Reprod Toxicol; 2012 Dec; 95(6):421-30. PubMed ID: 23213064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.
    Hart TK; Cook RM; Zia-Amirhosseini P; Minthorn E; Sellers TS; Maleeff BE; Eustis S; Schwartz LW; Tsui P; Appelbaum ER; Martin EC; Bugelski PJ; Herzyk DJ
    J Allergy Clin Immunol; 2001 Aug; 108(2):250-7. PubMed ID: 11496242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre- and postnatal development in the cynomolgus monkey following administration of ABT-874, a human anti-IL-12/23p40 monoclonal antibody.
    Enright BP; Tornesi B; Weinbauer GF; Blaich G
    Birth Defects Res B Dev Reprod Toxicol; 2012 Dec; 95(6):431-43. PubMed ID: 23212752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune complex disease in a chronic monkey study with a humanised, therapeutic antibody against CCL20 is associated with complement-containing drug aggregates.
    Laffan SB; Thomson AS; Mai S; Fishman C; Kambara T; Nistala K; Raymond JT; Chen S; Ramani T; Pageon L; Polsky R; Watkins M; Ottolangui G; White JR; Maier C; Herdman M; Bouma G
    PLoS One; 2020; 15(4):e0231655. PubMed ID: 32325480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates.
    Miederer M; McDevitt MR; Sgouros G; Kramer K; Cheung NK; Scheinberg DA
    J Nucl Med; 2004 Jan; 45(1):129-37. PubMed ID: 14734685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of drug specific circulating immune complexes from in vivo cynomolgus monkey serum samples.
    Pierog P; Krishna M; Yamniuk A; Chauhan A; DeSilva B
    J Immunol Methods; 2015 Jan; 416():124-36. PubMed ID: 25462536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys.
    Rojas JR; Taylor RP; Cunningham MR; Rutkoski TJ; Vennarini J; Jang H; Graham MA; Geboes K; Rousselle SD; Wagner CL
    J Pharmacol Exp Ther; 2005 May; 313(2):578-85. PubMed ID: 15647331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical safety, pharmacokinetics, and pharmacodynamics of recombinant human interleukin-21 in cynomolgus macaques (Macaca fascicularis).
    Waggie KS; Holdren MS; Byrnes-Blake K; Pedersen S; Ponce R; Hughes S; Miller DM
    Int J Toxicol; 2012; 31(4):303-16. PubMed ID: 22723515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of cynomolgus monkeys in development of monoclonal antibody drugs.
    Iwasaki K; Uno Y; Utoh M; Yamazaki H
    Drug Metab Pharmacokinet; 2019 Feb; 34(1):55-63. PubMed ID: 29655914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of biomarkers of drug-induced kidney injury in cynomolgus monkeys treated with a triple reuptake inhibitor.
    Guha M; Heier A; Price S; Bielenstein M; Caccese RG; Heathcote DI; Simpson TR; Stong DB; Bodes E
    Toxicol Sci; 2011 Apr; 120(2):269-83. PubMed ID: 21258088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of maternal and fetal exposure to an IgG2 monoclonal antibody following biweekly intravaginal administration to cynomolgus monkeys throughout pregnancy.
    Moffat GJ; Davies R; Kwon G; Retter MW; Chellman GJ; Kanapuram S; Moore M; Loomis M; Wang W; Pyrah IT
    Reprod Toxicol; 2014 Sep; 48():132-7. PubMed ID: 24859271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative determination of humanized monoclonal antibody rhuMAb2H7 in cynomolgus monkey serum using a Generic Immunoglobulin Pharmacokinetic (GRIP) assay.
    Yang J; Ng C; Lowman H; Chestnut R; Schofield C; Sandlund B; Ernst J; Bennett G; Quarmby V
    J Immunol Methods; 2008 Jun; 335(1-2):8-20. PubMed ID: 18402977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonclinical safety of mavrilimumab, an anti-GMCSF receptor alpha monoclonal antibody, in cynomolgus monkeys: relevance for human safety.
    Ryan PC; Sleeman MA; Rebelatto M; Wang B; Lu H; Chen X; Wu CY; Hinrichs MJ; Roskos L; Towers H; McKeever K; Dixit R
    Toxicol Appl Pharmacol; 2014 Sep; 279(2):230-9. PubMed ID: 24937321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects.
    Halpern WG; Lappin P; Zanardi T; Cai W; Corcoran M; Zhong J; Baker KP
    Toxicol Sci; 2006 Jun; 91(2):586-99. PubMed ID: 16517838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and immunogenicity investigation of a human anti-interleukin-17 monoclonal antibody in non-naïve cynomolgus monkeys.
    Han C; Gunn GR; Marini JC; Shankar G; Han Hsu H; Davis HM
    Drug Metab Dispos; 2015 May; 43(5):762-70. PubMed ID: 25739974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.